<DOC>
	<DOCNO>NCT00999219</DOCNO>
	<brief_summary>This study investigate efficacy safety FK199B ( Zolpidem MR Tablet ) polysomnography patient insomnia , exclude patient schizophrenia manic-depressive psychosis .</brief_summary>
	<brief_title>A Study FK199B Compare Efficacy With Zolpidem Polysomnography Patients With Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Patient diagnose primary insomnia accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) Patients complain insomnia continuously 4 week longer Patient 's usual bedtime 9 p.m. 12 a.m. 4 week period prior initial screen Patient occasion sleep total ≥3 &lt; 6.5 hour 4 week period prior initial screen Patient 's usual wake time sleep onset single night ≥45 minute per night 4 week period prior initial screen Patients body weight ≥45 kg ≤85 kg , BMI ≥18.5 &lt; 30 Patients schizophrenia manicdepressive psychosis Patients insomnia cause physical disease include chronic obstructive pulmonary disease , bronchial asthma , fibrositis syndrome , chronic fatigue syndrome , rheumatic disease , climacteric disturbance , dermatitis atopic Patients circadian rhythm sleep disorder Patient work night shift Patients alcoholic sleep disorder Patients alcohol drug dependence history Patients insomnia relate drug include antiparkinson , antihypertensive , steroid drug Patients sleep apnea syndrome Patients restless legs syndrome periodic limb movement disorder Patients epileptic insomnia Patients smoke average 40 cigarette day Patients receive psychotropic drug hypnotic ( include anxiolytic antidepressant drug hypnotic effect ) within 4 week period prior initial screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>FK199B</keyword>
	<keyword>Zolpidem</keyword>
</DOC>